Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)

被引：0

作者：

Nieves Martinez Chanza

Louisa Soukane

Philippe Barthelemy

Aurélien Carnot

Thierry Gil

Vinciane Casert

Vincent Vanhaudenarde

Brieuc Sautois

Lionel Staudacher

Jan Van den Brande

Stephane Culine

Emmanuel Seront

Marco Gizzi

Simone Albisinni

Thibault Tricard

Jean Christophe Fantoni

Marianne Paesmans

Rafael Caparica

Thierry Roumeguere

Ahmad Awada

机构：

[1] Jules Bordet Institute,Hopital Erasme

[2] Université Libre de Bruxelles,Clinique Sainte

[3] Université Libre de Bruxelles,Elisabeth

[4] Institut de Cancérologie Strasbourg Europe ICANS,undefined

[5] Centre Oscar Lambret,undefined

[6] Centre Hospitalier Universitaire de Ambrois Paré,undefined

[7] UCL,undefined

[8] University Hospital of Liege (CHU Sart Tilman),undefined

[9] Hopital Paris Saint Joseph,undefined

[10] University Hospital Antwerp,undefined

[11] UZA,undefined

[12] Hopital Saint-Louis,undefined

[13] Hopital de Jolimont,undefined

[14] Grand Hopital de Charleroi,undefined

来源：

BMC Cancer | / 21卷

关键词：

Avelumab; Bladder cancer; Checkpoint inhibitor; Immunotherapy; Neoadjuvant; PD-1 blockade; Urothelial carcinoma;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004-AURA trial)
Chanza, Nieves Martinez
Soukane, Louisa
Barthelemy, Philippe
Carnot, Aurelien
Gil, Thierry
Casert, Vinciane
Vanhaudenarde, Vincent
Sautois, Brieuc
Staudacher, Lionel
Van den Brande, Jan
Culine, Stephane
Seront, Emmanuel
Gizzi, Marco
Albisinni, Simone
Tricard, Thibault
Fantoni, Jean Christophe
Paesmans, Marianne
Caparica, Rafael
Roumeguere, Thierry
Awada, Ahmad
BMC CANCER, 2021, 21 (01)
[2] Avelumab (A) as neoadjuvant therapy in patients (pts) with muscle-invasive urothelial carcinoma (MIUC): Survival data of AURA trial, Oncodistinct 004
Blanc, Jeremy
Carnot, Aurelien
Barthelemy, Philippe
Casert, Vinciane
Staudacher, Lionel
Van den Brande, Jan
Sautois, Brieuc
Vanhaudenarde, Vincent
Seront, Emmanuel
Debien, Veronique
Ameye, Lieveke
Kotecki, Nuria
Fantoni, Jean Christophe
Tricard, Thibault
Roumeguere, Thierry Andre
Awada, Ahmad
Chanza, Nieves Martinez
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] Avelumab as the basis of neoadjuvant regimen in platinum-eligible and -ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial.
Chanza, Nieves Martinez
Carnot, Aurelien
Barthelemy, Philippe
Casert, Vinciane
Staudacher, Lionel
Van Den Brande, Jan
Sautois, Brieuc
Vanhaudenarde, Vincent
Seront, Emmanuel
Debien, Veronique
Gil, Thierry
Paesmans, Marianne
Kotecki, Nuria
Ignatiadis, Michail
Albisinni, Simone
Fantoni, Jean Christophe
Tricard, Thibault
Diamond, Romain
Roumeguere, Thierry Andre
Awada, Ahmad
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[4] Usefulness of neoadjuvant chemotherapy in non-metastatic muscle-invasive bladder cancer
Esper Rueda, J. A.
Carrion Lopez, P.
Donate Moreno, M. J.
Herais Raya, L.
Sanchez Migallon, I. Diaz de Mera
Legido Gomez, O.
Rico Marco, S.
Martinez Ruiz, J.
Nogueron Martinez, E.
Salinas Sanchez, A. S.
ACTAS UROLOGICAS ESPANOLAS, 2021, 45 (04): : 300 - 308
[5] The promise and challenges of neoadjuvant immunotherapy in the management of non-metastatic muscle-invasive bladder cancer
Janisch, Florian
Rink, Michael
Shariat, Shahrokh F.
BJU INTERNATIONAL, 2020, 125 (06) : 753 - 755
[6] Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC)
Chanza, N. Martinez
Carnot, A.
Barthelemy, P.
Casert, V.
Sautois, B.
Van den Brande, J.
Vanhaudenarde, V.
Staudacher, L.
Seront, E.
Culine, S.
Gizzi, M.
Gil, T.
Paesmans, M.
Kotecki, N.
Ignatiadis, M.
Albisinni, S.
Fantoni, J. C.
Tricard, T.
Roumeguere, T.
Awada, A. H.
ANNALS OF ONCOLOGY, 2021, 32 : S683 - S683
[7] Phase II trial of escalating doses of neoadjuvant atezolizumab for patients with non-metastatic urothelial carcinoma ineligible for cisplatinbased neoadjuvant chemotherapy.
Koshkin, Vadim S.
Natesan, Divya
Zhang Li
Oh, David Yoonsuk
Porten, Sima P.
Meng, Maxwell
Pruthi, Raj
Aggarwal, Rahul Raj
Small, Eric Jay
Fong, Lawrence
Friedlander, Terence W.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[8] Nivolumab plus chemoradiotherapy in patients with non-metastatic muscle-invasive bladder cancer (nmMIBC), not undergoing cystectomy: A phase II, randomized study by the Hellenic GU Cancer Group
Kougioumtzopoulou, A.
Koutsoukos, K.
Zakopoulou, R.
Tzannis, K.
Kyriazoglou, A.
Damatopoulou, A.
Liontos, M.
Pispirigkou, M. K.
Ntoumas, K.
Stravodimos, K.
Mitropoulos, D.
Dellis, A.
Papatsoris, A.
Chrisofos, M.
Kardamakis, D.
Zygogianni, A.
Liakouli, Z.
Pissakas, G.
Bamias, A.
Kouloulias, V.
ANNALS OF ONCOLOGY, 2024, 35 : S1133 - S1134
[9] Use of neoadjuvant chemotherapy for non-metastatic muscle-invasive bladder cancer in Asia-Pacific
Kanesvaran, R.
Kikuchi, E.
Kitamura, H.
Ku, J. H.
Lee, L. S.
Lin, T-P.
Nishiyama, H.
Ng, A. C. F.
Ng, J.
Poon, D. M. C.
Seo, H. K.
Shamaileh, R. R.
Spiteri, C.
Tan, E. M.
Tran, B.
Tsai, Y-S.
ANNALS OF ONCOLOGY, 2022, 33 : S1491 - S1492
[10] Development and validation of competing risk nomograms for predicting cancer-specific mortality in non-metastatic patients with non-muscle invasive urothelial bladder cancer
Li, Shan
Wang, Jinkui
Zhang, Zhaoxia
Wu, Yuzhou
Liu, Zhenyu
Yin, Zhikang
Liu, Junhong
SCIENTIFIC REPORTS, 2024, 14 (01):

← 1 2 3 4 5 →